Product
Interferon β-1a
1 clinical trial
1 indication
Indication
Relapsing-Remitting Multiple SclerosisClinical trial
Open-Label, Randomized, Multicenter, Multiple-Dose,Active-Controlled, Parallel-Group, Efficacy and Safety Study of BG00012 in Children From 10 to Less Than 18 Years of Age With Relapsing-Remitting Multiple Sclerosis, With Optional Open-Label ExtensionStatus: Active (not recruiting), Estimated PCD: 2025-09-08